



Nanospectra

Biosciences, INC.

COMPANY OVERVIEW:

Nanospectra Biosciences is a medical device company that is commercializing particle-based therapies for the selective and precise thermal destruction of solid tumors while minimizing damage to healthy adjacent tissue and preserving critical structures. The company was founded on intellectual property from Rice University and collaborative research with scientists at MD Anderson Cancer Center.

COMPANY FACTS:

- Business Focus: Medical Technology; Cancer
- President & CEO: John Stroh
- Headquarters: 8285 El Rio, Suite 150 Houston, Texas, USA, 77054 713-842-2720
- Investor/Media Contact: JStroh@Nanospectra.com
- Founded: 2002
- Structure: Private; Angel Investors
- 2010 Sales: <\$50,000 (basic research material sales)
- Employees: 5-10
- Website: www.Nanospectra.com

MILESTONES:

- 2002: Commenced operations
- 2003: Successful demonstration of in vivo efficacy in animals
- 2006: Completed cGMP manufacturing facility
- 2007: Completed animal and laboratory toxicity/safety tests
- 2008: IDE sanctioned human clinical trial initiated for refractory head and neck cancer